Rémi DELANSORNE, CEO
Chief Executive Officer

Rémi DELANSORNE is 48 years old. He holds a veterinary doctorate from “Ecole Nationale Vétérinaire d’Alfort” and a PhD in life sciences from « Université Pierre et Marie Curie » (Paris VI). After a post-doctoral fellowship at the University of Texas Medical School in Houston, he joined the pharmaceutical industry in 1985 in Theramex, where he held several positions in pre-clinical R&D.until the company was integrated into the Merck Group (now Merck-Serono) in 2000. In 2002. Rémi Delansorne became Merck Global Head of Diabetes Research and responsible for the three preclinical sites in France. Then, he joined Hybrigenics in 2004 as Vice-President for R&D and was appointed CEO of the company in September 2005.

Jean-François DUFOUR-LAMARTINIE
Senior Director, Head of Clinical R&D

Jean-François Dufour-Lamartinie joined Hybrigenics in 2006 as Head of Clinical Research & Development. He has acquired a broad experience in the clinical development in oncology in his prior positions with pharmaceutical companies, clinical research organisations and as clinician at cancer research institutes such as the Institut Gustave Roussy. Before joining Hybrigenics, Jean-François Dufour-Lamartinie was Clinical Research Director of BioAlliance Pharma, a French biopharmaceutical company, for more than 3 years and contributed to the launch of their first drug on the market.

William joined Hybrigenics in 2010. William has worked in business development in the pharmaceutical industry since 2001 in both biotech (ExonHit Therapeutics in Paris, France) and BigPharma (Hoffmann La Roche in Switzerland as well as in the US). During this time he has worked on a broad variety of alliances and licensing deals between biotechs and mid-sized to large pharmaceutical companies, as well as with academic institutions. While at ExonHit, he also led the project team which successfully took EHT 0202 (ExonHit’s Alzheimer’s disease candidate) through its Phase 2a study. William holds an MBA from INSEAD and an engineering degree from HEI (Lille, France).

Guillaume Floch has served as Financial Director of Hybrigenics SA since June 2008. He obtained a DESCF Accounting degree. He started his career in an Audit office before joining the pharmaceutical industry in 2001. He served as Financial Controller at Elan France, where he became Financial and Administrative Manager. He also took part in the creation of Zeneus Pharma and then when the company was sold to Cephalon France two years later. He subsequently joined the European headquarters of this laboratory, with the position of Manager, Business Planning & Performance.